Abbott/Thoratec Corp. is recalling HeartMate II and HeartMate 3 Left Ventricular Assist System (LVAS) due to an issue called Extrinsic Outflow Graft Obstruction, (EOGO) . This happens when… read more.
Investigative olezarsen lowers triglyceride levels by about half at 6 months without noteworthy adverse effects, researchers from the BRIDGE-TIMI 73a trial reported on April 7, 2024 at the… read more.
When compared with similar patients who were only treated with drugs, patients with vulnerable atherosclerotic plaques in the arteries of their hearts have achieved a significantly reduced relative… read more.
By adding investigational lerodalcibep to their standard cholesterol-lowering treatment for a year, patients at high risk for a heart attack or stroke achieved a reduction of “bad” cholesterol… read more.
Using a web application to qualify individuals for treatment with a non-prescription statin closely matched the results of clinician assessments in determining a person’s eligibility for taking statins… read more.
Patients with severely elevated triglyceride levels who are therefore at risk of developing acute pancreatitis have achieved a 74% average reduction in triglyceride levels, when treated for 24… read more.
Novartis announced new data demonstrating the early addition of twice-yearly Leqvio (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density… read more.
The majority of patients diagnosed with ACS/Acute Coronary Syndromes, including heart attacks and chest pain caused by decreased blood flow to the heart, appear to be able to… read more.
Individuals with heart disease stand to gain the most from a low-sodium diet but, on average, consume over twice the recommended daily sodium intake, according to a study… read more.
CSL Vifor announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of… read more.
The HeartMate Touch Communication System monitors patients who have an implantable HeartMate 3 Left Ventricular Assist Device. The HeartMate Touch Communication System works with the HeartMate System Controller…. read more.
Researchers report that depressed patients have an increased risk of developing cardiovascular disease (CVD), and that more women than men experience CVD after a depression diagnosis. The findings… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
